AZN Astrazeneca Plc

TIDMAZN

RNS Number : 3556R

AstraZeneca PLC

26 June 2015

AstraZeneca PLC - Change in ADS ratio

AstraZeneca PLC (the "Company") today announces an intended ratio change to its NYSE-listed sponsored Level 2 American Depositary Receipt ("ADR") programme. The current ratio is one (1) American Depositary Share ("ADS") per one (1) Ordinary Share. The new ratio will be two (2) ADSs per one (1) Ordinary Share. The expected effective date for the ratio change is 27 July 2015. There will be no change to the underlying Ordinary Shares.

ADS holders at the close of business New York time on the record date, 22 July 2015, will receive a distribution of one additional ADS for every ADS held. The new ADSs are expected to be distributed on 24 July 2015. No action is required by ADS holders to effect this change.

Contact details for Citibank, N.A., the Company's ADR depositary, can be found below.

A C N Kemp

Company Secretary

26 June 2015

CONTACT

Citibank Shareholder Services

 
 PO Box 43077     Tel (toll free in the US): +1-888-697-8018 
  Providence       Tel (outside the US): +1-781-575-4555 
  RI 02940-3077 
  US 
 

Media Enquiries

 
 Esra Erkal-Paler   +44 20 7604 8030 (UK/Global) 
 Jacob Lund         +46 8 553 260 20 (Sweden) 
 Michele Meixell    + 1 302 885 6351 (US) 
 

Investor Enquiries

 
 UK 
 Thomas Kudsk Larsen                                 +44 20 7604 8199   mob: +44 7818 524185 
 Eugenia Litz           Respiratory, Inflammation    +44 20 7604 8233   mob: +44 7884 735627 
                         and Autoimmunity 
 Nick Stone             Cardiovascular                 +44 1763 263     mob: +44 7717 618834 
                         and                                994 
                         Metabolic Disease 
 Karl Hård         Oncology                     +44 20 7604 8123   mob: +44 7789 654364 
 Craig Marks            Infection, Neuroscience      +44 20 7604 8591   mob: +44 7881 615764 
                         and Gastrointestinal 
                         Disease 
 Christer Gruvris                                    +44 20 7604 8126   mob: +44 7827 836825 
 US 
 Dial / Toll-Free                                      301-398-3251         866-381-7277 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCLLFFIRIIRFIE

Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024

Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024